Anthony Iudica, MD
Family Medicine · Harrisonburg, VANPI 1265433932
Payments from drug & device makers
Across 527 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$863
- Boehringer Ingelheim$797
- Pfizer$741
- AbbVie$709
- Lilly USA, LLC$520
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,57799%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 90 | $1,170 |
| AstraZeneca | 49 | $863 |
| Boehringer Ingelheim | 44 | $797 |
| Pfizer | 53 | $741 |
| AbbVie(2 entities) | 66 | $709 |
| Lilly USA, LLC | 42 | $520 |
| Amarin Pharma, Inc. | 43 | $467 |
| Amgen | 33 | $411 |
| E.r. Squibb & Sons, L.L.C. | 18 | $310 |
| Abbott | 14 | $203 |
| GSK | 12 | $196 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $187 |
| Johnson & Johnson | 8 | $143 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Novartis | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $73 |
| Biohaven Pharmaceuticals, Inc. | 2 | $53 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Merck | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Antares Pharma, Inc. | 2 | $48 |
| Sanofi Pasteur Inc. | 3 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Atricure, Inc. | 1 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Bayer | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Circassia Inc. | 1 | $11 |
| Organogenesis Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$125
- NURTEC ODT$109
How this compares
$7,619 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 90 | $94,343 |
| EliquisApixaban | 90 | $94,311 |
| OzempicSemaglutide | 47 | $84,067 |
| JardianceEmpagliflozin | 73 | $76,202 |
| XareltoRivaroxaban | 52 | $66,427 |
| TrulicityDulaglutide | 25 | $41,931 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $37,729 |
| MounjaroTirzepatide | 18 | $34,341 |
| JanuviaSitagliptin Phosphate | 25 | $22,106 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $16,250 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $11,630 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $11,280 |
| Atorvastatin Calcium | 978 | $8,830 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,492 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $5,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $741 | $95,741120 claims |
| AstraZenecaFarxiga | $863 | $94,34390 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $797 | $94,32497 claims |
| Novo NordiskOzempic | $1,170 | $84,06747 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $520 | $76,27243 claims |
| Johnson & JohnsonXarelto | $143 | $66,42752 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $196 | $53,97969 claims |
| MerckJanuvia, Janumet | $51 | $33,38642 claims |
| AbbVieSynthroid | $709 | $2,14051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Harrisonburg
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.